deoxycytidine has been researched along with Ewing Sarcoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castañeda, A; Cruz, J; Cruz, O; de Alava, E; de Torres, C; Garcia Del Muro, X; Lopez-Pousa, A; Maradiegue, E; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Mora, J; Perez-Jaume, S; Valverde, C; Vaz, MA | 1 |
| Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW | 1 |
| Gordon, DJ; Goss, KL | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
3 trial(s) available for deoxycytidine and Ewing Sarcoma
| Article | Year |
|---|---|
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Odds Ratio; Prognosis; Prospective Studies; Sarcoma, Ewing; Spain; Survival Rate; Taxoids | 2017 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
2 other study(ies) available for deoxycytidine and Ewing Sarcoma
| Article | Year |
|---|---|
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Phosphoproteins; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2018 |
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Ciclopirox; Cloning, Molecular; Deoxycytidine; DNA Damage; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Neoplasm Transplantation; Nuclear Proteins; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Pyridones; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA-Binding Protein EWS; RNA, Small Interfering; S Phase; Sarcoma, Ewing; Transcriptome | 2016 |